Research programme: angiogenesis inhibitors - Novartis/Rigel
Alternative Names: Angiogenesis inhibitors research programme - Novartis/RigelLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Novartis; Rigel Pharmaceuticals
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 11 Nov 2005 No development reported - Preclinical for Cancer in USA (unspecified route)
- 15 Dec 2003 This programme is still in active development
- 06 Jul 2001 Preclinical development for Cancer in USA (Unknown route)